Effects of different adjuvants with recombinant goose parvovirus vaccine induce protective immunity in waterfowl

• Main Authors: Ting-Ying Yen, 顏廷穎
• Other Authors: Chun-Yen Chu
• Format: Others
• Language: zh-TW
• Published: 2008
• Online Access: http://ndltd.ncl.edu.tw/handle/69943018722995646001

碩士 === 國立屏東科技大學 === 動物疫苗科技研究所 === 96 === Goose parvovirus (GPV) infection is one of the important diseases of goslings and ducklings in Taiwan. Derzy’s disease is a highly contagious disease in geese and young Muscovy ducks. The younger the bird affected the more acute the condition and the higher the mortality. GPV is single-stranded Parvovirinae belong to the family of Parvoviridae. It is generally causes many clinical symptoms including in reduced feed intake, nasal discharge, reddening of skin, profuse white diarrhea and growth retardation in geese. At present, the commercial traditional inactivated or attenuated virus vaccine are used to prevent GPV infection, but the efficacy is controversial. It is urgency to develop new modern vaccine and reduce the economical loss. In previous study, we have known that viral protein, VP2 is the main target for neutralizing antibodies in GPV and undergoes glycosylation during maturation. We had expressed VP2 recombinant protein by baculovirus expression system which has advantages of post-translational modifications and cheaper than mammalians cells. The objective of our study is to evaluate effects of different immunoadjuvant like aluminum adjuvant, oil adjuvant, and two kind of CpG ODN to help recombinant GPV subunit vaccine to increase immunity in waterfowl. In our preliminary results, we found one of CpG ODNs could enhance recombinant vaccine more than commercial oil adjuvant. The similar sequences that we designed could enhance humoral response in ducks. In the proceeding experiments, we try to clarify the regulation mechanism of CpG motif by detecting IFN-γ level and calculating the CD4+/CD8+ T cells ratio after immunization in ducks. The data indicated designed CpG motif could induce lymphocytes and CD8+ T cells proliferation. CpG ODN adjuvant may have an application of future GPV subunit vaccine development.